Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Letter to the Editor

Volume 8, Number 6, June 2016, pages 486-488

An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors

Figure

Figure 1.
Figure 1. The changes in HbA1c (a), body weight (b) and ALT (c) at 1, 2, 3 and 6 months after the start of SGLT2 inhibitors in the low eGFR group and the high eGFR group. *P < 0.05 and **P < 0.01 vs. the high eGFR group by the paired Student’s t-test, respectively. ALT: alanine aminotransferase; eGFR: estimated glomerular filtration rate; SGLT2: sodium-glucose cotransporter 2.

Tables

Table 1. Baseline Characteristics of Subjects Who Had Taken SGLT2 Inhibitors (n = 48)
 
Baseline characteristics
Age (years)48 ± 11
Sex (male/female)16/32
Body height (cm)161 ± 8
Body weight (kg)85.2 ± 17.9
Body mass index (BMI) (kg/m2)32.2 ± 6.0
Systolic blood pressure (mm Hg)130 ± 15
Diastolic blood pressure (mm Hg)80 ± 11
Alanine aminotransferase (IU/L)52 ± 41
eGFR (mL/min/1.73 m2)93 ± 35
Plasma glucose (mg/dL)178 ± 75
HbA1c (%)8.9 ± 2.0

 

Table 2. SGLT2 Inhibitors Prescribed to Subjects at Baseline (n = 48)
 
SGLT2 inhibitors
Dapagliflozin 5 mg18 (38%)
Ipragliflozin 25 mg3 (6%)
Ipragliflozin 50 mg9 (19%)
Tofogliflozin 20 mg6 (13%)
Luseogliflozin 2.5 mg10 (46%)
Canagliflozin 100 mg1 (2%)
Empagliflozin 10 mg1 (2%)